Concept:
Antidiabetic drugs lower blood glucose by different routes — some increase insulin release (secretagogues/incretin-based), while others improve insulin sensitivity. This is an "except" question, so we look for the one that does NOT boost insulin secretion.
Step 1: Exenatide is a GLP-1 receptor agonist — it stimulates glucose-dependent insulin secretion. Alogliptin is a DPP-4 inhibitor — it raises incretin levels, indirectly increasing insulin secretion. Glibenclamide is a sulfonylurea — it directly stimulates pancreatic β-cells to release insulin.
Step 2: Rosiglitazone is a thiazolidinedione (PPAR-γ agonist). It works by improving insulin sensitivity in muscle, fat and liver — it is an insulin sensitiser, NOT a secretagogue.
Answer: Option (4) — Rosiglitazone improves insulin sensitivity rather than enhancing insulin secretion. (4)